Personalized early detection and prevention of breast cancer: ENVISION consensus statement.


Journal

Nature reviews. Clinical oncology
ISSN: 1759-4782
Titre abrégé: Nat Rev Clin Oncol
Pays: England
ID NLM: 101500077

Informations de publication

Date de publication:
11 2020
Historique:
accepted: 06 05 2020
pubmed: 20 6 2020
medline: 11 2 2021
entrez: 20 6 2020
Statut: ppublish

Résumé

The European Collaborative on Personalized Early Detection and Prevention of Breast Cancer (ENVISION) brings together several international research consortia working on different aspects of the personalized early detection and prevention of breast cancer. In a consensus conference held in 2019, the members of this network identified research areas requiring development to enable evidence-based personalized interventions that might improve the benefits and reduce the harms of existing breast cancer screening and prevention programmes. The priority areas identified were: 1) breast cancer subtype-specific risk assessment tools applicable to women of all ancestries; 2) intermediate surrogate markers of response to preventive measures; 3) novel non-surgical preventive measures to reduce the incidence of breast cancer of poor prognosis; and 4) hybrid effectiveness-implementation research combined with modelling studies to evaluate the long-term population outcomes of risk-based early detection strategies. The implementation of such programmes would require health-care systems to be open to learning and adapting, the engagement of a diverse range of stakeholders and tailoring to societal norms and values, while also addressing the ethical and legal issues. In this Consensus Statement, we discuss the current state of breast cancer risk prediction, risk-stratified prevention and early detection strategies, and their implementation. Throughout, we highlight priorities for advancing each of these areas.

Identifiants

pubmed: 32555420
doi: 10.1038/s41571-020-0388-9
pii: 10.1038/s41571-020-0388-9
pmc: PMC7567644
doi:

Types de publication

Consensus Development Conference Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

687-705

Subventions

Organisme : Cancer Research UK
ID : 27223
Pays : United Kingdom

Commentaires et corrections

Type : ErratumIn

Références

Nature. 2010 Nov 4;468(7320):98-102
pubmed: 20881962
Lancet. 2016 Jun 25;387(10038):2602
pubmed: 27353820
Genome Res. 2010 Apr;20(4):440-6
pubmed: 20219944
Nat Med. 2016 Aug;22(8):933-9
pubmed: 27322743
J Clin Oncol. 2019 Apr 20;37(12):954-963
pubmed: 30625040
BMJ. 2016 Mar 15;352:i1102
pubmed: 26979548
Carcinogenesis. 2007 Aug;28(8):1726-30
pubmed: 17494053
Nat Rev Genet. 2016 Jul;17(7):392-406
pubmed: 27140283
Endocr Relat Cancer. 2012 Apr 10;19(2):137-47
pubmed: 22199143
BMC Womens Health. 2018 Nov 26;18(1):192
pubmed: 30477482
Genet Med. 2005 Sep;7(7):495-500
pubmed: 16170241
JAMA. 2006 Jun 21;295(23):2727-41
pubmed: 16754727
Carcinogenesis. 2008 Jul;29(7):1367-72
pubmed: 18566018
Lancet. 2015 Apr 11;385(9976):1397-405
pubmed: 25579834
J Natl Cancer Inst. 2020 Sep 1;112(9):929-937
pubmed: 31845728
Nat Genet. 2017 Dec;49(12):1767-1778
pubmed: 29058716
Lancet. 2019 Sep 28;394(10204):1159-1168
pubmed: 31474332
Ann Behav Med. 2017 Oct;51(5):718-729
pubmed: 28290066
J Public Health (Oxf). 2007 Sep;29(3):246-50
pubmed: 17526507
Med Care. 2013 Apr;51(4):295-300
pubmed: 23269114
Nat Commun. 2016 Jan 29;7:10478
pubmed: 26823093
Cancer Epidemiol Biomarkers Prev. 2010 Sep;19(9):2143-51
pubmed: 20826828
Genet Med. 2019 Aug;21(8):1708-1718
pubmed: 30643217
Nature. 2010 Jun 10;465(7299):803-7
pubmed: 20445538
J Natl Cancer Inst. 1989 Dec 20;81(24):1879-86
pubmed: 2593165
Breast. 2018 Jun;39:139-147
pubmed: 29610032
Genet Med. 2006 Jul;8(7):448-50
pubmed: 16845278
Urol Clin North Am. 2014 May;41(2):223-8
pubmed: 24725484
Arch Plast Surg. 2016 Jul;43(4):328-38
pubmed: 27462565
Hum Mol Genet. 2011 Aug 15;20(16):3289-303
pubmed: 21596841
Cancer. 2019 Aug 15;125(16):2829-2836
pubmed: 31206626
PLoS One. 2019 Feb 14;14(2):e0211918
pubmed: 30763406
JAMA. 2019 Aug 20;322(7):652-665
pubmed: 31429903
PLoS One. 2020 Feb 5;15(2):e0228198
pubmed: 32023287
Lancet Oncol. 2015 Jan;16(1):67-75
pubmed: 25497694
Ann Intern Med. 2013 Apr 16;158(8):604-14
pubmed: 23588749
Ann Intern Med. 2002 Sep 3;137(5 Part 1):305-12
pubmed: 12204013
J Public Health (Oxf). 2014 Jun;36(2):285-91
pubmed: 23986542
Int J Qual Health Care. 2006 Oct;18(5):377-82
pubmed: 16951425
JAMA. 2019 Sep 3;322(9):857-867
pubmed: 31479144
Science. 2018 Feb 23;359(6378):926-930
pubmed: 29348365
J Natl Cancer Inst. 1986 Aug;77(2):317-20
pubmed: 3461193
JAMA Oncol. 2018 Nov 1;4(11):1504-1510
pubmed: 29978189
J Med Screen. 2020 Sep;27(3):138-145
pubmed: 31701797
Stat Med. 2004 Apr 15;23(7):1111-30
pubmed: 15057881
Radiology. 2019 Jul;292(1):60-66
pubmed: 31063083
PLoS Med. 2010 May 25;7(5):e1000279
pubmed: 20520800
JAMA. 2011 Sep 7;306(9):989-90
pubmed: 21900139
Lancet Oncol. 2019 Apr;20(4):504-517
pubmed: 30799262
JAMA. 2009 Oct 21;302(15):1685-92
pubmed: 19843904
Psychooncology. 2019 May;28(5):1056-1062
pubmed: 30848018
Lancet. 2008 Feb 16;371(9612):569-78
pubmed: 18280327
Public Health Res Pract. 2019 Jul 31;29(2):
pubmed: 31384885
J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88
pubmed: 9747868
Cancer Prev Res (Phila). 2010 Jun;3(6):696-706
pubmed: 20404000
Bull World Health Organ. 2008 Apr;86(4):317-9
pubmed: 18438522
JAMA Oncol. 2016 Oct 01;2(10):1295-1302
pubmed: 27228256
Implement Sci. 2009 Oct 19;4:67
pubmed: 19840381
Qual Health Care. 2001 Sep;10 Suppl 1:i55-60
pubmed: 11533440
Am J Hum Genet. 2019 Jan 3;104(1):21-34
pubmed: 30554720
Genet Med. 2015 Dec;17(12):949-57
pubmed: 25764215
PLoS One. 2014 Feb 03;9(2):e86858
pubmed: 24498285
Int J Cancer. 2012 Dec 15;131(12):2898-902
pubmed: 22461063
Breast Cancer Res. 2016 Sep 20;18(1):91
pubmed: 27645219
J Clin Oncol. 2005 Mar 10;23(8):1636-43
pubmed: 15755971
Breast Cancer Res. 2016 Dec 6;18(1):122
pubmed: 27923387
PLoS One. 2009 Dec 18;4(12):e8274
pubmed: 20019873
J Natl Cancer Inst. 2011 May 4;103(9):744-52
pubmed: 21483019
Breast. 2013 Jun;22(3):344-50
pubmed: 22981738
Ann Intern Med. 2008 Mar 4;148(5):337-47
pubmed: 18316752
Lancet. 2019 Sep 28;394(10204):1139
pubmed: 31474331
Prog Mol Biol Transl Sci. 2017;151:1-32
pubmed: 29096890
Breast Cancer Res. 2018 Dec 13;20(1):152
pubmed: 30545395
BMJ Open. 2018 Dec 28;8(12):e023789
pubmed: 30593552
Health Care Manage Rev. 2019 Apr/Jun;44(2):183-194
pubmed: 28671876
MDM Policy Pract. 2016 Aug 23;1(1):2381468316665365
pubmed: 30288405
J Gen Intern Med. 2010 Jan;25 Suppl 1:50-5
pubmed: 20077152
Lancet. 2015 Apr 25;385(9978):1642-52
pubmed: 25701273
J Natl Cancer Inst. 2020 Mar 1;112(3):278-285
pubmed: 31165158
Br J Cancer. 2015 Feb 3;112(3):562-6
pubmed: 25535731
Breast Cancer Res Treat. 2019 Oct;177(3):723-733
pubmed: 31302855
Postgrad Med J. 2016 Jul;92(1089):369-71
pubmed: 27001864
Lancet. 2002 Sep 14;360(9336):817-24
pubmed: 12243915
Br J Cancer. 2019 Jul;121(1):76-85
pubmed: 31114019
Breast. 2018 Feb;37:148-153
pubmed: 29161653
J Natl Cancer Inst. 2003 Aug 20;95(16):1218-26
pubmed: 12928347
Psychiatry Res. 2019 Oct;280:112513
pubmed: 31434011
Breast Cancer Res. 2019 May 17;21(1):62
pubmed: 31101124
Br J Cancer. 2018 May;118(9):1268-1275
pubmed: 29681615
Mutagenesis. 2013 Nov;28(6):683-97
pubmed: 24113799
Nat Genet. 2013 Apr;45(4):349-51
pubmed: 23535723
Endocr Relat Cancer. 2014 Mar 12;21(2):T33-55
pubmed: 24532474
Genet Med. 2019 Jul;21(7):1497-1506
pubmed: 30504931
BMC Health Serv Res. 2017 Jan 26;17(1):88
pubmed: 28126032
Breast. 2019 Feb;43:39-47
pubmed: 30445378
Med Decis Making. 2012 Sep-Oct;32(5):667-77
pubmed: 22990082
Value Health. 2012 Sep-Oct;15(6):843-50
pubmed: 22999134
Lancet. 1999 Jun 5;353(9168):1903-8
pubmed: 10371567
Clin Epidemiol. 2019 Jul 11;11:543-561
pubmed: 31372057
Int J Cancer. 2020 Aug 15;147(4):931-939
pubmed: 31863475
Lancet. 2002 Mar 16;359(9310):909-19
pubmed: 11918907
N Engl J Med. 2015 Jun 4;372(23):2243-57
pubmed: 26014596
JAMA Intern Med. 2014 Aug;174(8):1413-4
pubmed: 25090177
JAMA Surg. 2018 Feb 1;153(2):123-129
pubmed: 28903167
Br J Cancer. 2015 Jul 28;113(3):548-55
pubmed: 26079301
NPJ Breast Cancer. 2017 Sep 13;3:34
pubmed: 28944288
N Engl J Med. 2005 Jul 21;353(3):229-37
pubmed: 16034008
J Natl Cancer Inst. 2015 Mar 04;107(5):
pubmed: 25745020
Z Arztl Fortbild Qualitatssich. 2005;99(6):343-51
pubmed: 16121649
Nat Commun. 2019 Nov 22;10(1):5296
pubmed: 31757951
Sci Transl Med. 2013 Apr 24;5(182):182ra55
pubmed: 23616122
Med Decis Making. 2012 Sep-Oct;32(5):722-32
pubmed: 22990087
J Clin Oncol. 2017 Jul 10;35(20):2232-2239
pubmed: 28402748
Br J Cancer. 2018 Jun;118(12):1648-1657
pubmed: 29736008
Lancet. 2020 Mar 7;395(10226):785-794
pubmed: 31492501
N Engl J Med. 2016 Oct 13;375(15):1438-1447
pubmed: 27732805
BMC Cancer. 2019 Jun 10;19(1):557
pubmed: 31182048
N Engl J Med. 2011 Jun 23;364(25):2381-91
pubmed: 21639806
Lancet. 1998 Jul 11;352(9122):98-101
pubmed: 9672274
Lancet. 2006 Dec 9;368(9552):2053-60
pubmed: 17161727
Nat Rev Cancer. 2018 Jan;18(1):19-32
pubmed: 29217838
Breast Cancer Res Treat. 2019 Apr;174(3):741-748
pubmed: 30603998
J Natl Cancer Inst. 2017 Jan 27;109(5):
pubmed: 28130475
Ann Intern Med. 2012 May 1;156(9):635-48
pubmed: 22547473
Lancet Oncol. 2019 Mar;20(3):339-351
pubmed: 30795951
JAMA. 2019 Jan 22;321(3):288-300
pubmed: 30667505
Value Health. 2003 Jan-Feb;6(1):9-17
pubmed: 12535234
Public Health Rev. 2019 Feb 28;40:2
pubmed: 30858992
Genet Med. 2020 Feb;22(2):407-415
pubmed: 31406321
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
pubmed: 11553815
Value Health. 2007 Sep-Oct;10(5):336-47
pubmed: 17888098
EBioMedicine. 2015 Sep 09;2(10):1331-9
pubmed: 26629528
Lancet. 2014 Mar 22;383(9922):1041-8
pubmed: 24333009
Public Health Genomics. 2018;21(1-2):37-44
pubmed: 30223261
J Natl Cancer Inst. 2020 Mar 1;112(3):295-304
pubmed: 31143935
Clin Pharmacol Ther. 2010 Dec;88(6):729-33
pubmed: 21081937
Cancer Cell. 2015 Nov 9;28(5):666-676
pubmed: 26525104
J Natl Cancer Inst. 2014 Nov 12;106(11):
pubmed: 25392194
Lancet Oncol. 2013 Sep;14(10):1009-19
pubmed: 23890780
J Pers Med. 2021 Jun 04;11(6):
pubmed: 34199804
Public Health Res Pract. 2019 Jul 31;29(2):
pubmed: 31384886
Hum Mutat. 2019 Sep;40(9):1557-1578
pubmed: 31131967
J Clin Oncol. 2017 Aug 20;35(24):2838-2847
pubmed: 28692382
Nature. 2010 Nov 4;468(7320):103-7
pubmed: 20881963
Ann Intern Med. 2012 Mar 6;156(5):340-9
pubmed: 22393129
BMC Cancer. 2019 Dec 4;19(1):1089
pubmed: 31795966
Science. 2006 Dec 1;314(5804):1467-70
pubmed: 17138902
Nat Rev Cancer. 2017 Apr;17(4):223-238
pubmed: 28233803
Proc Natl Acad Sci U S A. 2016 Aug 16;113(33):9327-32
pubmed: 27457926
Eur J Hum Genet. 2019 Mar;27(3):340-348
pubmed: 30401960
Br J Cancer. 2008 Apr 22;98(8):1457-66
pubmed: 18349832
Lancet Oncol. 2013 Nov;14(12):1226-32
pubmed: 24140203
Breast. 2018 Jun;39:24-32
pubmed: 29529454
J Natl Cancer Inst. 2015 Nov 18;108(3):
pubmed: 26582245
Br J Cancer. 2020 Mar;122(5):726-732
pubmed: 31919405
Br J Cancer. 2002 Nov 18;87(11):1234-45
pubmed: 12439712
Nature. 2017 Nov 2;551(7678):92-94
pubmed: 29059683
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Natl Cancer Inst. 2007 Feb 21;99(4):283-90
pubmed: 17312305
Trends Genet. 2017 May;33(5):299-302
pubmed: 28365141
BMJ. 2016 Aug 09;354:i3857
pubmed: 27510511
Lancet. 1998 Jul 11;352(9122):93-7
pubmed: 9672273
Int J Epidemiol. 2018 Apr 1;47(2):526-536
pubmed: 29315403
Breast Cancer Res. 2017 Oct 18;19(1):114
pubmed: 29047382
Breast. 2015 Jun;24(3):237-41
pubmed: 25708717
J Natl Cancer Inst. 2011 Feb 2;103(3):250-63
pubmed: 21191117
Int J Cancer. 2019 Oct 1;145(7):1782-1797
pubmed: 31050813
Med Decis Making. 2019 Jan;39(1):41-56
pubmed: 30799691
Genet Med. 2018 Apr;20(4):390-396
pubmed: 28796238
Ann Intern Med. 2016 Nov 15;165(10):700-712
pubmed: 27548583
Clin Cancer Res. 2004 Mar 15;10(6):2029-34
pubmed: 15041722
Breast Cancer Res Treat. 2014 Feb;144(1):103-11
pubmed: 24469641
J Epidemiol Community Health. 2002 Feb;56(2):119-27
pubmed: 11812811
J Clin Oncol. 2016 Aug 10;34(23):2750-60
pubmed: 27269948
Br J Cancer. 2015 Feb 3;112(3):580-93
pubmed: 25422909
Br J Cancer. 2018 May;118(9):1155-1161
pubmed: 29681616
Nat Rev Clin Oncol. 2018 May;15(5):292-309
pubmed: 29485132
J Epidemiol Community Health. 2006 Mar;60(3):208-12
pubmed: 16476749
BMC Med Ethics. 2014 Aug 16;15:64
pubmed: 25127662
Nature. 2012 Apr 18;486(7403):346-52
pubmed: 22522925
Lancet. 2003 Jan 25;361(9354):296-300
pubmed: 12559863
Cochrane Database Syst Rev. 2016 Nov 29;11:CD008932
pubmed: 27898991
J Natl Cancer Inst. 2020 Jan 1;112(1):87-94
pubmed: 30989176
J Pers Med. 2015 Jun 09;5(2):191-212
pubmed: 26068647

Auteurs

Nora Pashayan (N)

Department of Applied Health Research, Institute of Epidemiology and Healthcare, University College London, London, UK.

Antonis C Antoniou (AC)

Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.

Urska Ivanus (U)

Epidemiology and Cancer Registry, Institute of Oncology Ljubljana, Ljubljana, Slovenia.

Laura J Esserman (LJ)

Carol Franc Buck Breast Care Center, University of California, San Francisco, CA, USA.

Douglas F Easton (DF)

Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.

David French (D)

Division of Psychology & Mental Health, School of Health Sciences, University of Manchester, Manchester, UK.

Gaby Sroczynski (G)

Department of Public Health, Health Services Research and Health Technology Assessment, Institute of Public Health, Medical Decision Making and Health Technology Assessment, UMIT-University for Health Sciences, Medical Informatics and Technology, Hall in Tirol, Austria.
Division of Health Technology Assessment, Oncotyrol - Center for Personalized Cancer Medicine, Innsbruck, Austria.

Per Hall (P)

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Department of Oncology, Södersjukhuset, Stockholm, Sweden.

Jack Cuzick (J)

Wolfson Institute of Preventive Medicine, Barts and The London, Centre for Cancer Prevention, Queen Mary University of London, London, UK.

D Gareth Evans (DG)

Division of Evolution and Genomic Sciences, University of Manchester, Manchester, UK.

Jacques Simard (J)

Genomics Center, CHU de Québec - Université Laval Research Center, Québec, Canada.

Montserrat Garcia-Closas (M)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.

Rita Schmutzler (R)

Center of Family Breast and Ovarian Cancer, University Hospital Cologne, Cologne, Germany.

Odette Wegwarth (O)

Max Planck Institute for Human Development, Center for Adaptive Rationality, Harding Center for Risk Literacy, Berlin, Germany.

Paul Pharoah (P)

Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Department of Oncology, University of Cambridge, Cambridge, UK.

Sowmiya Moorthie (S)

PHG Foundation, Cambridge, UK.

Sandrine De Montgolfier (S)

IRIS Institute for Interdisciplinary Research on Social Issues, Paris, France.

Camille Baron (C)

Unicancer, Paris, France.

Zdenko Herceg (Z)

Epigenetic Group, International Agency for Research on Cancer (IARC), WHO, Lyon, France.

Clare Turnbull (C)

Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK.

Corinne Balleyguier (C)

Department Medical Imaging, Institut Gustave Roussy, Villejuif, France.

Paolo Giorgi Rossi (PG)

Epidemiology Unit, Azienda USL di Reggio Emilia - IRCCS, Reggio Emilia, Italy.

Jelle Wesseling (J)

Division of Molecular Pathology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.

David Ritchie (D)

Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.

Marc Tischkowitz (M)

Department of Medical Genetics, National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK.

Mireille Broeders (M)

Department for Health Evidence, Radboud University Medical Center, Nijmegen, Netherlands.

Dan Reisel (D)

Department of Women's Cancer, Institute for Women's Health, University College London, London, UK.

Andres Metspalu (A)

The Estonian Genome Center, Institute of Genomics, University of Tartu, Tartu, Estonia.

Thomas Callender (T)

Department of Applied Health Research, Institute of Epidemiology and Healthcare, University College London, London, UK.

Harry de Koning (H)

Department of Public Health, Erasmus MC, Rotterdam, Netherlands.

Peter Devilee (P)

Department of Human Genetics, Department of Pathology, Leiden University Medical Centre, Leiden, Netherlands.

Suzette Delaloge (S)

Breast Cancer Department, Gustave Roussy Institute, Paris, France.

Marjanka K Schmidt (MK)

Division of Molecular Pathology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.

Martin Widschwendter (M)

Department of Women's Cancer, Institute for Women's Health, University College London, London, UK. M.Widschwendter@ucl.ac.uk.
Universität Innsbruck, Innsbruck, Austria. M.Widschwendter@ucl.ac.uk.
European Translational Oncology Prevention and Screening (EUTOPS) Institute, Hall in Tirol, Austria. M.Widschwendter@ucl.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH